Therapeutic Potential of Various Beta-glucan Sources in Conjunction with Anti-tumor Monoclonal Antibody in Cancer Therapy
Michael Driscoll, Richard Hansen, Chuanlin Ding, Daniel E. Cramer and Jun Yan*
*Tumor Immunobiology Program; James Graham Brown Cancer Center; University of Louisville; Louisville, Kentucky USA
Cancer Biology & Therapy 8:3, 216-223; 1 February 2009.
Combined [WGP® 3-6] β-glucan with anti-tumor mAb therapy has demonstrated therapeutic efficacy in murine tumor models. The current study was designed to compare the therapeutic efficacy of various sources of β-glucans. Our studies demonstrated that yeast β-glucan, in combination with anti-tumor mAb, resulted in significantly smaller tumor burdens and achieved enhanced long-term survival compared to mAb alone or β-glucan extracts from mushrooms. Further studies indicated that yeast β-glucan particle was superior to mushroom extracts in inducing cytokine secretion, particularly IL-12 production in dendritic cells (DCs). In addition, results showed that cytokine production was markedly decreased in MyD88-deficient macrophages and DCs but not in complement receptor 3 (CR3)-deficient mice. Our data suggest that yeast β-glucan demonstrates much stronger adjuvant activity compared to mushroom β-glucan extracts in tumor therapy. This effect of yeast β-glucan may be in part ascribed to the cytokine secretion by DCs and macrophages and bioavailability of active β-glucan moiety.
Published at wellmune.com on 19 February 2009